US 11389481
Allogeneic cell therapy of B cell malignancies using genetically engineered T cells targeting CD19
granted A61KA61K2039/505A61K2239/31
Quick answer
US patent 11389481 (Allogeneic cell therapy of B cell malignancies using genetically engineered T cells targeting CD19) held by CRISPR THERAPEUTICS AG expires Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- CRISPR THERAPEUTICS AG
- Grant date
- Tue Jul 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 20
- CPC classes
- A61K, A61K2039/505, A61K2239/31, A61K2239/38, A61K31/7076